Pediatric Nephrology

, Volume 27, Issue 9, pp 1465–1476

Non-viral infections in children after renal transplantation

Educational Review


Renal transplantation has long been recognised as the gold standard treatment for children with end-stage renal failure. There has been an improvement over the years in patient and renal allograft survival because of improved immunosuppression, surgical techniques and living kidney donation. Despite reduced acute allograft rejection rates, non-viral infections continue to be a serious complication for paediatric renal transplant recipients (RTR). The risk of infections in RTR is determined by the pre-transplantation immunisation status, post-transplant exposure to potential pathogens and the amount of immunosuppression. The greatest risk of life-threatening and Cytomegalovirus infections is during the first 6 months post-transplant owing to a high immunosuppressive burden. The potential sources of bacterial infections are donor derived, transplant medium fluid, peritoneal and haemodialysis catheter and transplant ureteric stent. Urinary tract infections are frequent in patients with lower urinary tract dysfunction and can result in renal allograft damage. This review outlines the incidence, timing, risk factors, prevention and treatment of non-viral infections in paediatric RTR by critically reviewing current immunosuppressive regimens, their risk–benefit ratio in order to optimise renal allograft survival with reduced rates of rejection and infectious complications.


Paediatric renal transplantation Non-viral infection Immunosuppression minimisation Risk of infection Graft survival 


  1. 1.
    Fine RN (1985) Renal transplantation for children—the only realistic choice. Kidney Int Suppl 17:15–17Google Scholar
  2. 2.
    Ingelfinger JR, Grupe WE, Harmon WE, Femback SK, Levey RH (1981) Growth acceleration following renal transplantation in children less than 7 years of age. Pediatrics 68:255–259PubMedGoogle Scholar
  3. 3.
    Dharnidharka VR, Caillard S, Agodoa LY, Abbott KC (2006) Infection frequency and profile in different age groups of kidney transplant recipients. Transplantation 27:1662–1667CrossRefGoogle Scholar
  4. 4.
    NAPRTCS 2005 annual report, available at
  5. 5.
    Groothoff JW, Gruppen MP, Offringa M, Hutten J, Lilien MR, Van De Kar NJ, Wolff ED, Davin JC, Heymans HS (2002) Mortality and causes of death of endstage renal disease in children: a Dutch cohort study. Kidney Int 61:621–629PubMedCrossRefGoogle Scholar
  6. 6.
    Van Damme-Lombaerts R, Herman J, Coosemans W,Pirenne J (2001) Pediatric renal transplantation: a single Belgian center experience over 20 years. Pediatr Transplant 5:447–451PubMedCrossRefGoogle Scholar
  7. 7.
    Johnson RJ, Armstrong S, Belger MA, Fuggle SV, Martin S, Middleton D, Ray TC, Rigden SP, Verrier-Jones K, Morris PJ (2002) Paediatric Task Force of United Kingdom, Bristol, UK: the outcome of pediatric cadaveric renal transplantation in the UK and Eire. Pediatr Transplant 6:367–377PubMedCrossRefGoogle Scholar
  8. 8.
    Harzallah K, Floret D, Martin X, Cochat P (2004) Mortality in pediatric renal transplants: 15 years’ experience. Arch Pediatr 11:916–920PubMedCrossRefGoogle Scholar
  9. 9.
    Rees L, Shroff R, Hutchinson C, Fernando ON, Trompeter RS (2007) Long-term outcome of paediatric renal transplantation: follow-up of 300 children from 1973 to 2000. Nephron Clin Pract 105:c68–c76PubMedCrossRefGoogle Scholar
  10. 10.
    Dharnidharka VR, Stablein DM, Harmon WE (2004) Post-transplant infections now exceed acute rejection as cause for hospitalization: a report of the NAPRTCS. Am J Transplant 4:384–389PubMedCrossRefGoogle Scholar
  11. 11.
    Harmon WE (1991) Opportunistic infections in children following renal transplantation. Pediatr Nephrol 5:118–125PubMedCrossRefGoogle Scholar
  12. 12.
    Rubin RH (1993) Infectious disease complications of renal transplantation. Kidney Int 44:221–236PubMedCrossRefGoogle Scholar
  13. 13.
    Bilal J, Nicholls K, Becker GJ, Walker RG (1999) Impact of acute rejection therapy on infections and malignancies in renal transplant recipients. Transplantation 68:1597–1603CrossRefGoogle Scholar
  14. 14.
    Fishman JA (2007) Infection in solid-organ transplant recipients. N Engl J Med 357:2601–2614PubMedCrossRefGoogle Scholar
  15. 15.
    Fishman JA, Rubin RH (1998) Infection in organ transplant recipients. N Engl J Med 24:1743–1752Google Scholar
  16. 16.
    Rubin RH, Wolfson JS, Cosimi AB, Tolkoff-Rubin NE (1981) Infections in renal transplant recipients. Am J Med 70:405–411PubMedCrossRefGoogle Scholar
  17. 17.
    Fishman JA (2007) Infection in renal transplant recipients. Semin Nephrol 27:445–461PubMedCrossRefGoogle Scholar
  18. 18.
    Rubin RH, Cosimi AB, Tolkoff-Rubin NE, Russell PS, Hirsch MS (1977) Infectious disease syndromes attributable to cytomegalovirus and their significance among renal transplant recipients. Transplantation 24:458–464PubMedCrossRefGoogle Scholar
  19. 19.
    Rubin RH, Sester M, Gärtner BC (1989) The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 261:3607–3609PubMedCrossRefGoogle Scholar
  20. 20.
    Fonseca-Aten M, Michaels MG (2006) Infections in pediatric solid organ transplant recipients. Semin Pediatr Surg 15:153–161PubMedCrossRefGoogle Scholar
  21. 21.
    Leigh JDA (1971) Bacteraemia in patients receiving human cadaveric renal transplants. Pathol Clin 24:295–299CrossRefGoogle Scholar
  22. 22.
    Tolkoff-Rubin NE, Rubin RH (1992) Opportunistic fungal and bacterial infection in the renal transplant recipient. J Am Soc Nephrol 2:S264–S269PubMedGoogle Scholar
  23. 23.
    DeVault GA Jr, King JW, Rohr MS, Landreneau MD, Brown ST, McDonald JC (1990) Opportunistic infections with Strongyloides stercoralis in renal transplantation. Rev Infect Dis 12:653–671PubMedCrossRefGoogle Scholar
  24. 24.
    Fernandez-Guerrero ML, Aguado JM, Buzon L, Barros C, Montalbán C, Martín T, Bouza E (1987) Visceral leishmaniasis in immunocompromised hosts. Am J Med 83:1098–1102PubMedCrossRefGoogle Scholar
  25. 25.
    Gourishankar S, Doucette K, Fenton J, Purych D, Kowlewska-Grochowska K, Preiksaitis J (2008) The use of donor and recipient screening for toxoplasma in the era of universal trimethoprim sulphametoxazole prophylaxis. J Transplant 85:980–985CrossRefGoogle Scholar
  26. 26.
    Anderson CB, Haid SD, Hruska KA, Etheredge EA (1978) Significance of microbial contamination of stored cadaver kidneys. Arch Surg 113:269–271PubMedCrossRefGoogle Scholar
  27. 27.
    Benoit G, Tiguert R, Bensadoun H, Hammoudi Y, Hiesse C, Jacques L, Fries D, Jardin A (1988) Incidence of transport medium contamination in cadaver kidney procurement. Transplant Proc 20:895PubMedGoogle Scholar
  28. 28.
    Mora M, Wilms H, Kirste G (1991) Significance of bacterial contamination of cadaver donor renal allografts before transplantation. Transplant Proc 23:2648PubMedGoogle Scholar
  29. 29.
    Bijnen AB, Weimar W, Dik P, Oberop H, Jeekel J (1984) The hazard of transplanting contaminated kidneys. Transplant Proc: 16:27Google Scholar
  30. 30.
    McCoy GC, Loening S, Braun WE, Magnusson MO, Banowsky LH, McHenry MC (1975) The fate of cadaver renal allografts contaminated before transplantation. Transplantation 20:467PubMedCrossRefGoogle Scholar
  31. 31.
    Wilson CH, Gregory RT, Wheeler JR, Hurwitz RL, Vansant JH, Thomas FT (1979) Complications of end-to-side renal artery anastomosis in renal transplant infection. Vasc Surg 13:207CrossRefGoogle Scholar
  32. 32.
    Doig RL, Boyd PJR, Eykyn S (1975) Staphylococcus aureus transmitted in transplanted kidneys. Lancet 9:243CrossRefGoogle Scholar
  33. 33.
    Wakelin SJ, Casey J, Robertson A, Friend P, Bryon C, Hester Yorke J, Rigden SP, Xavier EFS, Pareja-Cebrian L, Forsythe JLR, Morris PJ (2005) The incidence and importance of bacterial contaminants of cadaveric renal perfusion fluid. Transpl Int 17:680–686PubMedCrossRefGoogle Scholar
  34. 34.
    Arbeiter K, Pichler A, Muerwald G, Mueller T, Bidmon B, Balzar E, Ruffingshofer D, Greenbaum L, Aufricht C (2001) Timing of peritoneal dialysis catheter removal after pediatric renal transplantation. Perit Dial Int 21:467–470PubMedGoogle Scholar
  35. 35.
    Palmer JA, Kaiser BA, Polinsky MS, Dunn SP, Braas C, Waltz R, Baluarte HJ (1994) Peritoneal dialysis catheter infections in children after renal transplantation: choosing the time of removal. Pediatr Nephrol 8:715–718PubMedCrossRefGoogle Scholar
  36. 36.
    Wilson CH, Bhatti AB, Rix DA, Manas DM (2005) Routine intraoperative ureteric stenting for kidney transplant recipients. Cochrane Database Syst Rev 19:4 CD004925Google Scholar
  37. 37.
    Patel P, Olsburgh J, Marks SD (2010) Timing of ureteric stent removal in pediatric renal transplant recipients (RTR). Pediatr Nephrol 25:1779–2004CrossRefGoogle Scholar
  38. 38.
    Mueller T, Resinger C, Ruffingshofer D, Arbeiter K, Balzar E, Aufricht C (2003) Urinary tract infections beyond the early posttransplant period in pediatric renal graft recipients. Wien Klin Wochenschr 115:385–388PubMedCrossRefGoogle Scholar
  39. 39.
    Ranchin B, Chapuis F, Dawhara M, Canterino I, Hadj-Aissa A, Said MH, Parchoux B, Dubourg L, Pouillaude JM, Floret D, Martin X, Cochat P (2000) Vesicoureteral reflux after kidney transplantation in children. Nephrol Dial Transplant 15:1852–1858PubMedCrossRefGoogle Scholar
  40. 40.
    Dunn SP, Vinocur CD, Hanevold C, Wagner CW, Weintraub WH (1987) Pyelonephritis following pediatric renal transplant: increased incidence with vesicoureteral reflux. J Pediatr Surg 22:1095–1099PubMedCrossRefGoogle Scholar
  41. 41.
    Neuhaus TJ, Schwobel M, Schlumpf R, Offner G, Leumann E, Willi U (1997) Pyelonephritis and vesicoureteral reflux after renal transplantation in young children. J Urol 157:1400–1403PubMedCrossRefGoogle Scholar
  42. 42.
    Audard V, Amor M, Desvaux D, Pastural M, Baron C, Philippe R, Pardon A, Dahmane D, Lang P, Grimbert P (2005) Acute graft pyelonephritis: a potential cause of acute rejection in renal transplant. Transplantation 80:1128–1130PubMedCrossRefGoogle Scholar
  43. 43.
    Chuang P, Parikh CR, Langone A (2005) Urinary tract infections after renal transplantation: a retrospective review at two US transplant centers. Clin Transplant 19:230–235PubMedCrossRefGoogle Scholar
  44. 44.
    Sharifian M, Rees L, Trompeter RS (1998) High incidence of bacteriuria following renal transplantation in children. Nephrol Dial Transplant 13:432–435PubMedCrossRefGoogle Scholar
  45. 45.
    Ergin F, Arslan H, Yapar G, Karakayali H, Haberal M (2003) Urinary tract infections in renal transplant recipients. Transplant Proc 35:2685–2686PubMedCrossRefGoogle Scholar
  46. 46.
    Cairns HS, Spencer S, Hilson AJ, Rudge CJ, Neild GH (1994) 99mTc-DMSA imaging with tomography in renal transplant recipients with abnormal lower urinary tracts. Nephrol Dial Transplant 9:1157–1161PubMedGoogle Scholar
  47. 47.
    Coulthard MG, Keir MJ (2006) Reflux nephropathy in kidney transplants, demonstrated by dimercaptosuccinic acid scanning. Transplantation 82:205–210PubMedCrossRefGoogle Scholar
  48. 48.
    Hutchinson C, Beckett M, Kiratli P, Gordon I, Trompeter RS, Rees L (2003) The significance of a defect on DMSA scan in children with renal transplants. Pediatr Transplant 7:441–445PubMedCrossRefGoogle Scholar
  49. 49.
    Ali-El-Dein B, Abol-Enein H, El-Husseini A, Osman Y, Shehab El-Din AB, Ghoneim MA (2004) Renal transplantation in children with abnormal lower urinary tract. Transplant Proc 36:2968–2973PubMedCrossRefGoogle Scholar
  50. 50.
    Otukesh H, Sharifian M, Simfroosh N, Basiri A, Hoseini R, Sedigh N, Golnari P, Rezai M, Fereshtenejad M (2005) Outcome of renal transplantation in children with low urinary tract abnormality. Transplant Proc 37:3071–3074PubMedCrossRefGoogle Scholar
  51. 51.
    Mendizabal S, Estornell F, Zamora I, Sabater A, Ibarra FG, Simon J (2005) Renal transplantation in children with severe bladder dysfunction. J Urol 173:226–229PubMedCrossRefGoogle Scholar
  52. 52.
    Franc-Guimond J, Gonzalez R (2004) Renal transplantation in children with reconstructed bladders. Transplantation 77:1116–1120PubMedCrossRefGoogle Scholar
  53. 53.
    Neild GH, Dakmish A, Wood S, Nauth-Misir R, Woodhouse CR (2004) Renal transplantation in adults with abnormal bladders. Transplantation 77:1123–1127PubMedCrossRefGoogle Scholar
  54. 54.
    Ross JH, Kay R, Novick AC, Hayes JM, Hodge EE, Streem SB (1994) Long-term results of renal transplantation into the valve bladder. J Urol 151:1500–1504PubMedGoogle Scholar
  55. 55.
    Riley P, Marks SD, Desai DY, Mushtaq I, Koffman G, Mamode N (2010) Dysfunction challenges facing renal transplantation in pediatric patients with lower urinary tract. Transplantation 89(11):1299–1307PubMedCrossRefGoogle Scholar
  56. 56.
    Casale P, Grady RW, Mitchell ME, Healey P (2005) Recurrent urinary tract infection in the post-transplant reflux nephropathy patient: is reflux in the native ureter the culprit? Pediatr Transplant 9:324–327PubMedCrossRefGoogle Scholar
  57. 57.
    Basiri A, Otookesh H, Simforoosh N, Hosseini R, Hosseini-Moghaddam SM, Sharifian M (2006) Does pre-transplantation antireflux surgery eliminate post-renal transplantation pyelonephritis in children? J Urol 175:1490–1492PubMedCrossRefGoogle Scholar
  58. 58.
    Luke PP, Herz DB, Bellinger MF, Chakrabarti P, Vivas CA, Scantlebury VP, Hakala TR, Jevnikar AM, Jain A, Shapiro R, Jordan ML (2003) Long-term results of pediatric renal transplantation into a dysfunctional lower urinary tract. Transplantation 76:1578–1582PubMedCrossRefGoogle Scholar
  59. 59.
    Lopez Pereira P, Jaureguizar E, Martinez Urrutia MJ, Meseguer C, Navarro M (2000) Does treatment of bladder dysfunction prior to renal transplant improve outcome in patients with posterior urethral valves? Pediatr Transplant 4:118–122PubMedCrossRefGoogle Scholar
  60. 60.
    Ozcan O, Tekgul S, Duzova A, Aki F, Yuksel S, Bakkaloglu A, Erkan I, Bakkaloglu M (2006) How does the presence of urologic problems change the outcome of kidney transplantation in the pediatric age group. Transplant Proc 38:552–553PubMedCrossRefGoogle Scholar
  61. 61.
    John U, Kemper JM (2009) Urinary tract infection after renal transplantation. Pediatr Nephrol 24:1129–1136PubMedCrossRefGoogle Scholar
  62. 62.
    Flynn JT, Frisch K, Kershaw DB, Sedman AB, Bunchman TE (1999) Response to early measles-mumps-rubella vaccination in infants with chronic renal failure and/or receiving peritoneal dialysis. Adv Perit Dial 15:269–272PubMedGoogle Scholar
  63. 63.
    Kruger S, Mueller-Steinhardt M, Kirchner H, Kreft B (2001) A 5-year follow-up on antibody response after diphtheria and tetanus vaccination in hemodialysis patients. Am J Kidney Dis 38:1264–1270PubMedCrossRefGoogle Scholar
  64. 64.
    Webb NJ (2000) Immunization against varicella in end stage and pre-end stage renal failure. Arch Dis Child 82:141–143PubMedCrossRefGoogle Scholar
  65. 65.
    Jha V, Kohli HS, Sud K, Gupta KL, Minz M, Joshi K, Sakhuja V (1999) Laryngeal tuberculosis in renal transplant recipients. Transplantation 68:153–155PubMedCrossRefGoogle Scholar
  66. 66.
    Prelog M, Zimmerhackl LB (2010) Varicella vaccination in pediatric kidney and liver transplantation. Pediatr Transplant 14:41–47PubMedCrossRefGoogle Scholar
  67. 67.
    Yazaki H, Goto N, Uchida K, Kobayashi T, Gatanaga H, Oka S (2009) Outbreak of Pneumocystis jiroveci pneumonia in renal transplant recipients: P. jiroveci is contagious to the susceptible host. Transplantation 88:380–385PubMedCrossRefGoogle Scholar
  68. 68.
    EBPG Expert Group on Renal Transplantation (2002) European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV. 7.1 Late infections. Pneumocystis carinii pneumonia. Nephrol Dial Transplant 17 [Suppl 4]:36Google Scholar
  69. 69.
    Rabodonirina M, Vanhems P, Couray-Targe S, Gillibert RP, Ganne C, Nizard N, Colin C, Fabry J, Touraine JL, van Melle G, Nahimana A, Francioli P, Hauser PM (2004) Molecular evidence of interhuman transmission of Pneumocystis pneumonia among renal transplant recipients hospitalised with HIV-infected patients. Emerg Infect Dis 10:1766PubMedCrossRefGoogle Scholar
  70. 70.
    Hocker B, Wendt C, Nahimana A, Tönshoff B, Hauser PM (2005) Molecular evidence of Pneumocystis transmission in pediatric transplant unit. Emerg Infect Dis 11:330PubMedCrossRefGoogle Scholar
  71. 71.
    De Boer MG, Bruijnesteijn van Coppenraet LE, Gaasbeek A, Berger SP, Gelinck LB, van Houwelingen HC, van den Broek P, Kuijper EJ, Kroon FP, Vandenbroucke JP (2007) An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients: interhuman transmission or a common environmental source? Clin Infect Dis 44:1143PubMedCrossRefGoogle Scholar
  72. 72.
    Schmoldt S, Schuhegger R, Wendler T, Huber I, Söllner H, Hogardt M, Arbogast H, Heesemann J, Bader L, Sing A (2008) Molecular evidence of nosocomial Pneumocystis jirovecii transmission among 16 patients after kidney transplantation. J Clin Microbiol 46:966PubMedCrossRefGoogle Scholar
  73. 73.
    Fontana I, Ginevri F, Arcuri V, Basile G, Nocera A, Beatini M, Bonato L, Barocci S, Bertocchi M, Manolitsi O, Valente R, Draghi P, Gusmano R, Valente U (1999) Vesico-ureteral reflux in pediatric kidney transplants: clinical relevance to graft and patient outcome. Pediatr Transplant 3:206–209PubMedCrossRefGoogle Scholar
  74. 74.
    Tolkoff-Rubin NE, Cosimi AB, Russell PS, Rubin RH (1982) A controlled study of trimethoprim-sulfamethoxazole prophylaxis of urinary tract infection in renal transplant recipients. Rev Infect Dis 4:614–618PubMedCrossRefGoogle Scholar
  75. 75.
    Fox BC, Sollinger HW, Belzer FO, Maki DG (1990) A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis. Am J Med 89:255–274PubMedCrossRefGoogle Scholar
  76. 76.
    Harmon WE, McDonald RA, Reyes JD, Bridges ND, Sweet SC, Sommers CM, Guidinger MK (2005) Pediatric transplantation, 1994–2003. Am J Transplant 5:887–903PubMedCrossRefGoogle Scholar
  77. 77.
    Baron PW, Ojogho ON, Yorgin P, Sahney S, Cutler D, Ben-Youssef R, Baqai W, Weissman J, Franco E, Zuppan C, Concepcion W (2008) Comparison of outcomes with low dose anti-thymocyte globulin, basiliximab or no induction therapy in pediatric kidney transplant recipients: a retrospective study. Pediatr Transplant 12:32–39PubMedCrossRefGoogle Scholar
  78. 78.
    Flaman F, Zieroth S, RaoV RH, Delgado DH (2006) Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation. J Heart LungTransplant 25:1358–1362CrossRefGoogle Scholar
  79. 79.
    Puliyandaa DP, Stableinb DM, Dharnidharkac VR (2007) Younger age and antibody induction increase the risk for infection in pediatric renal transplantation: a NAPRTCS Report. Am J Transplant 7:662–666CrossRefGoogle Scholar
  80. 80.
    Ettenger RB (1999) Antibody therapy as an induction regimen in pediatric renal transplantation. Transplant Proc 31:2677–2678PubMedCrossRefGoogle Scholar
  81. 81.
    Mourad G, Rostaing L, Legendre C, Garrigue V, Thervet E, Durand D (2004) Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 78:584–590PubMedCrossRefGoogle Scholar
  82. 82.
    Lebranchu Y, Bridoux F, Buchler M, Le Meur Y, Etienne I, Toupance O, Hurault de Ligny B, Touchard G, Moulin B, Le Pogamp P, Reigneau O, Guignard M, Rifle G (2002) Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF containing triple therapy. Am J Transplant 2:48–56PubMedCrossRefGoogle Scholar
  83. 83.
    Clark G, Walsh G, Deshpande P, Koffman G (2002) Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation. Nephrol Dial Transplant 17:1304–1309PubMedCrossRefGoogle Scholar
  84. 84.
    Halloran PF (2004) Immunosuppressive drugs for kidney transplantation. N Engl J Med 351(26):2715–2729PubMedCrossRefGoogle Scholar
  85. 85.
    Fortun J, Martin-Davila P, Pascual J, Cervera C, Moreno A, Gavalda J, Aguado JM, Pereira P, Gurguí M, Carratala J, Fogueda M, Montejo M, Blasco F, Bou G, Torre-Cisneros J, RESITRA Transplant Network (2010) Immunosuppressive therapy and infection after kidney transplantation. Transpl Infect Dis. doi:10.1111/j.1399-3062.2010.00526.x
  86. 86.
    Knight RJ, Villa M, Laskey R, Benavides C, Schoenberg L, Welsh M, Kerman RH, Podder H, Van Buren CT, Katz SM, Kahan BD (2007) Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients. Clin Transplant 21:460–465PubMedCrossRefGoogle Scholar
  87. 87.
    Grim SA, Slover CM, Sankary H, Oberholzer J, Benedetti E, Clark NM (2006) Risk factors for wound healing complications in sirolimus-treated renal transplant recipients. Transplant Proc 38:3520–3523PubMedCrossRefGoogle Scholar
  88. 88.
    Valente JF, Hricik D, Weigel K, Seaman D, Knauss T, Siegel CT, Bodziak K, Schulak JA (2003) Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant 3:1128–1134PubMedCrossRefGoogle Scholar
  89. 89.
    McWilliams TJ, Levvey BJ, Russell PA, Milne DG, Snell GI (2003) Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation. J Heart LungTransplant 22:210–213CrossRefGoogle Scholar
  90. 90.
    Howard L, Gopalan D, Griffiths M, Mahadeva R (2006) Sirolimus-induced pulmonary hypersensitivity associated with a CD4 T-cell infiltrate. Chest 129:1718–1721PubMedCrossRefGoogle Scholar
  91. 91.
    Pham PT, Pham PC, Danovitch GM, Ross DJ, Gritsch HA, Kendrick EA, Singer J, Shah T, Wilkinson AH (2004) Sirolimus-associated pulmonary toxicity. Transplantation 77:1215–1220PubMedCrossRefGoogle Scholar
  92. 92.
    Marty FM, Bryar J, Browne SK, Schwarzberg T, Ho VT, Bassett IV, Koreth J, Alyea EP, Soiffer RJ, Cutler CS, Antin JH, Baden LR (2007) Sirolimus-based graft-versus host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 110:490–500PubMedCrossRefGoogle Scholar
  93. 93.
    Ozaki KS, Camara NO, Nogueira E, Pereira MG, Granato C, Melaragno C, Camargo LF, Pacheco-Silva A (2007) The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients. Clin Transplant 21:675–680PubMedCrossRefGoogle Scholar
  94. 94.
    Trotter JF, Wallack A, Steinberg T (2003) Low incidence of cytomegalovirus disease in liver transplant recipients receiving sirolimus primary immunosuppression with 3-day corticosteroid taper. Transpl Infect Dis 5:174–180PubMedCrossRefGoogle Scholar
  95. 95.
    Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, Starling RC, Sørensen K, Hummel M, Lind JM, Abeywickrama KH, Bernhardt P, RAD B253 Study Group (2003) Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349:847–858PubMedCrossRefGoogle Scholar
  96. 96.
    Vitko S, Margreiter R, Weimar W, Dantal J, Viljoen HG, Li Y, Jappe A, Cretin N, RAD B201 Study Group (2004) Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 78:1532–1540PubMedCrossRefGoogle Scholar
  97. 97.
    Mathew TH (1998) A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 65:1450–1454PubMedCrossRefGoogle Scholar
  98. 98.
    Fisher RA, Stone JJ, Wolfe LG, Rodgers CM, Anderson ML, Sterling RK, Shiffman ML, Luketic VA, Contos MJ, Mills AS, Ferreira-Gonzalez A, Posner MP (2004) Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation. Clin Transplant 18:463–472PubMedCrossRefGoogle Scholar
  99. 99.
    Kobashigawa J, Miller L, Renlund D, Mentzer R, Alderman E, Bourge R, Costanzo M, Eisen H, Dureau G, Ratkovec R, Hummel M, Ipe D, Johnson J, Keogh A, Mamelok R, Mancini D, Smart F, Valantine H (1998) A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 66:507–515PubMedCrossRefGoogle Scholar
  100. 100.
    Webster AC, Caring for Australians with Renal Impairment (CARI) (2007) The CARI guidelines. Calcineurin inhibitors in renal transplantation: the addition of anti-CD25 antibody induction to standard immunosuppressive therapy for kidney transplant recipients. Nephrology 12:S75–S84PubMedCrossRefGoogle Scholar
  101. 101.
    Jose M, Caring for Australians with Renal Impairment (CARI) (2007) The CARI guidelines. Calcineurin inhibitors in renal transplantation: adverse effects. Nephrology 12:S66–S74PubMedCrossRefGoogle Scholar
  102. 102.
    Gea-Banacloche JC, Opal SM, Jorgensen J, Carcillo JA, Sepkowitz KA, Cordonnier C (2004) Sepsis associated with immunosuppressive medications: an evidence-based review. Crit Care Med 32[11 Suppl]:S578–S590PubMedCrossRefGoogle Scholar
  103. 103.
    Kamara N, Miliotoa O, Puissant-Lubranoc B, Espositoa L, Pierrea MC, Ould Mohameda Lavayssierea A, Cointaulta O, Ribesa D, Cardeaua I, Nogiera MB, Duranda D, Abbalc M, Blancherc A, Rostainga L (2010) Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 10:89–98CrossRefGoogle Scholar

Copyright information

© IPNA 2012

Authors and Affiliations

  1. 1.Department of Paediatric NephrologyGreat Ormond Street Hospital for Children NHS TrustLondonUK

Personalised recommendations